Perrigo has signed an exclusive licensing agreement with Highland Pharmaceuticals, a St. Louis, Missouri-based pharmaceutical company, for Highland’s Tarex methamphetamine-blocking technology and the distribution rights of Zephrex-D (pseudoephedrine HCI 30 mg), a product developed using the Tarex technology for blocking one of the more common domestic methods of illegal methamphetamine production.

Highland’s Tarex technology is a lipid-based drug delivery system that provides tamper-resistance to frequently abused drugs, according to the company. The technology uses a proprietary blend of ingredients that surround a given drug to impede extraction of the active ingredient from the formulation via solvents, according to the company.

Perrigo plans to integrate the Tarex technology into certain of its store-brand and retailer-own label pseudoephedrine hydrochloric acid products in the future and will immediately distribute Zephrex D to its retail customers.

Source: Perrigo